Drugs / balapiravir
balapiravir
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01096576 | Jul 2010 → Apr 2011 | dengue disease | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | balapiravir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01096576 ↗ |
| Known as | Balapiravir hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL550936 ↗ |
| Known as | BALAPIRAVIR HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL550936 ↗ |
| Known as | R-1626 | ChEMBL registry synonym — accepted as the source's own label CHEMBL550936 ↗ |
| Known as | RO-4588161-001 | ChEMBL registry synonym — accepted as the source's own label CHEMBL550936 ↗ |
| Known as | RO4588161 | “balapiravir [RO4588161]” NCT01096576 ↗ |
| Action | Inhibit | “a polymerase inhibitor” PMID 22807519 ↗ Jul 2012 |
| Modality | Small molecule | “Balapiravir is a prodrug of a nucleoside analogue (called R1479)” PMID 22807519 ↗ Jul 2012 |
| Route | Oral | “Patients will be randomized to receive either balapiravir or placebo, orally twice daily for 5 days.” NCT01096576 ↗ |